Supply Chain
One of the comments I hear often from healthcare financial executives is that they are continuously being pushed to "do more with less." I hear this in relation to workforce management, revenue cycle process improvements, changing reimbursement models, automation efforts and IT projects.
The global market for infertility drugs and devices will reach nearly $4.8 billion in 2017, said a recent report from Transparency Market Research.
Relationships between healthcare organizations and physicians are a growing trend within the industry as more doctors become employees of hospitals. Building healthy working relationships between the two factions is important.
A recent report from J.D. Power and Associates indicates that customers are becoming less satisfied with purchasing prescriptions through mail-order pharmacies as compared to brick and mortar locations, especially in the area of cost.
For the first time in decades, sales of vaccines declined in 2011, due in large part to a weak flu season, said a recent report from healthcare market research publisher Kalorama Information.
Global competition and the impending medical device tax, set to begin Jan. 1, 2013, are creating challenges for the U.S. biomedical device industry, according to a new study by tax advisory firm WTP Advisors.
Ten major biopharmaceutical companies announced Wednesday that they have joined forces to form a nonprofit organization called TransCelerate BioPharma Inc., to accelerate the development of new medicines.
The global insulin market is expected to reach $32 billion by 2018, increasing at a compound annual growth rate of 12 percent from its 2011 market value of $12.4 billion, according to a new report from Transparency Market Research.
Based on information examined in its Budget Impact Projections report and the National Economic Impact Survey, supply contracting company Novation predicts supply chain costs will increase by 2.9 percent in 2013.
Medical device firm Welch Allyn announced Monday it will reduce its workforce by 10 percent over the next three years in reaction to the 2.3 percent medical device tax slated to begin in January 2013 in accordance with the Affordable Care Act.